Guardant Health Investor Presentation
Liquid biopsy for therapy selection in advanced cancer
GUARDANT 360
Market leading Comprehensive Liquid Biopsy
Guideline-complete clinical results for advanced
solid tumors in less than 7 days
GUARDANT OMNI
TM
>2MB footprint panel tailored for immuno-
oncology and targeted therapy development
GUARDANT 360
TM
REPORTING
Fal Report Dale: SEP-06-2018
Recept Date: AUG-31-2016
Collection Date MUD-00-2018
Specimen
Status
Blood
PHYSICIAN
Mary MO
Account Boca Raton Regional Hostal
Address: fat Street San Francisco, CA 94155
Ph: 310-829005 | Fax: 310291111
Apart
Summary of Somatic Alterations & Associated Treatment Options
KEM
%IDNA or
Amplification
Approved in atter indication
Associated
FDA-approved theracles
Clinical trial availability
EGFR T790M
0.7%
Oximet
Yes Nearby
Storih Gottinb. A
Yes Nona Nearby
EGFR E746 A750del
12.2%
None
EMLA-ALK Fusion
6.0%
♥Cris
Ves None Nearby
GOKS Action
Medium (++)
Palbocico
EGFR Anication
Low(
Alati Caberartinb
Yes None Nearby
Nechumush, Ptumab
TP53 7231
11.0%
None
Yes - None Nearby
GLM MOTC P3852
Functional consequences and inca sgrisanes of strees union, Revance of therapies targeting these one ran
This sequence change does not alter the ance and as posion and is ely to be a topic cacacoste
We evaluated 73 genes, including the following guideline-recommended genes for NSCLC
ЕСНЯ (стем на
EAREZ (HER)
ALK
ROST
BRAF
MERCK
AstraZeneca
MERCK Pfizer
Bristol-Myers Squibb
9
GUARDANT™View entire presentation